|
|
Volumn 28, Issue 12, 2010, Pages
|
|
Irinotecan in the adjuvant treatment of colon cancer: Is the story finished or does personalized therapy open new opportunities?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
7 ETHYL 10 HYDROXYCAMPTOTHECIN;
CARCINOEMBRYONIC ANTIGEN;
FLUOROURACIL;
FOLINATE CALCIUM;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DRUG DERIVATIVE;
CANCER ADJUVANT THERAPY;
CANCER STAGING;
COLON CANCER;
DISEASE FREE SURVIVAL;
DNA POLYMORPHISM;
DRUG DOSE REDUCTION;
DRUG METABOLISM;
DRUG WITHDRAWAL;
GENOTYPE;
HUMAN;
LETTER;
LYMPH NODE METASTASIS;
MULTICENTER STUDY (TOPIC);
OVERALL SURVIVAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
UNSPECIFIED SIDE EFFECT;
COLON TUMOR;
MORTALITY;
NOTE;
PATIENT SELECTION;
PERSONALIZED MEDICINE;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
CLINICAL TRIALS, PHASE III AS TOPIC;
COLONIC NEOPLASMS;
DISEASE-FREE SURVIVAL;
HUMANS;
INDIVIDUALIZED MEDICINE;
PATIENT SELECTION;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 77951639823
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2009.25.8558 Document Type: Letter |
|
Times cited : (4)
|
|
References (8)
|
